Medical Costs of Diabetic Complications Total Costs and Excess Costs by Age and Type of Treatment Results of the German CoDiM Study

Abstract

Aims: This study examined the medical costs of diabetic complications by age, type of treatment, and type of complication and researched the relationship between total and excess costs with respect to type of complications.

Methods: Patients with diabetes (n=26,971) were identified from a German statutory health insurance database by glucose-lowering drug prescriptions and ICD-10 diagnoses. Diabetes complications were defined as microvascular (eye and kidney diseases), foot complications (peripheral neuropathy, peripheral vascular disease), macrovascular (cardio- and cerebrovascular diseases), and uncontrolled glucose metabolism (glycaemic complications). Estimates of frequency and medical costs of complications were calculated for diabetic patients and an age- and sex-matched control group of persons without diabetes.

Results: Half (53%) of the medical costs per diabetes patient in 2001 (€4,457) were spent for management of complications (€2,380). In the control group, costs of these diseases were €761 per person. Consequently excess costs of complication due to diabetes were estimated at €1,619 (36%) and were caused for treatment of macrovascular (€643, 14%), microvascular (€458, 10%), foot complications (€430, 10%) and glycaemic complications (€88, 2%). Furthermore 12% were spent for management of hyperglycaemia (€542). Excess costs for complications per diabetic patient were higher for insulin (€4,395) versus non-insulin treated patients (€587). Eye, kidney and foot complications were encountered 3 - 4 times more often in diabetic patients than in non-diabetic controls, whereas macrovascular diseases were only 1.6 times more frequent. Therefore the proportion of diabetes dependent excess costs of microvascular and foot complications was high (78%), and was considerably lower (56%) for macrovascular complications.

Conclusions: A close relationship exists between diabetes related excess costs and the presence of microvascular and foot complications. It is important to identify these patients early in order to incorporate them into diabetes management programs. A better care of diabetes patients and subsequent prevention of these late complications promises not only to improve quality of life but also to be highly cost-effective.

cost - diabetes-dependent costs - diabetes mellitus - macrovascular complications - microvascular complications - foot complications - age - insulin - glucose-lowering drugs

References

• 1 American Diabetes Association . Economic consequences of diabetes mellitus in the US in 1997.  Diabetes Care. 1998;  21 296-309
• 2 American Diabetes Association . Economic costs of diabetes in the US in 2002.  Diabetes Care. 2003;  26 917-932
• 3 Brandle M, Zhou H, Smith BRK, Marriott D, Burke R, Tabaei BP. et al . The direct medical cost of type 2 diabetes.  Diabetes Care. 2003;  26 2300-2304
• 4 Brown JB, Nichols GA, Glauber HS, Bakst AW, Schaeffer M, Kelleher CC. Health care costs associated with escalation of drug treatment in type 2 diabetes mellitus.  Am J Health Syst Pharm. 2001;  58 151-157
• 5 DCCT . Resource utilization and costs of care in the diabetes control and complications trial.  Diabetes Care. 1995;  18 1468-1478
• 6 Detournay B, Fagnani F, Pribil C, Eschwege E. Consommation de soins et de biens médicaux des diabétiques de type 2 en France en 1998.  Diabetes Metab. 2000;  26 225-231 , (in French)
• 7 Engelgau MM, Geiss LS, Saaddine JB, Boyle JP, Benjamin SM, Gregg EW. et al . The evolving diabetes burden in the United States.  Ann Intern Med. 2004;  140 945-950
• 8 Ettaro L, Songer TJ, Zhang P, Engelgau MM. Cost-of-illness studies in diabetes mellitus.  Pharmacoeconomics. 2004;  22 149-164
• 9 Ferber von L, Salzsieder E, Hauner H, Thoelke H, Köster I, Jutzi E. et al . Diabetes prevalence from health insurance data: evaluation of estimates by comparison with a population-based diabetes register.  Diabetes Metab. 1993;  19 89-95
• 10 Ferber von L, Köster I, Hauner H. Costs of the treatment of hyperglycaemia in patients with diabetes mellitus. The impact of age, type of therapy and complications: Results of the German CoDiM study.  Med Klin. 2006;  101 384-393 , (in German)
• 11 Hauner H, Köster I, von Ferber L. Prävalenz des Diabetes mellitus in Deutschland 1998-2001. Sekundärdaten einer Versichertenstichprobe der AOK Hessen/KV Hessen.  Dtsch Med Wochensch. 2003;  128 2632-2637 , >(in German)
• 12 Henriksson F, Jönsson B. Diabetes: the cost of illness in Sweden.  J Intern Med. 1998;  244 461-468
• 13 Henriksson F, Agardh CD, Berne C, Bolinder J, Lönnqvist F, Stenström P. et al . Direct medical costs for patients with type 2 diabetes in Sweden.  J Intern Med. 2000;  248 387-396
• 14 Ihle P, Köster I, Herholz H, Rambow-Bertram P, Schardt T, Schubert I. Versichertenstichprobe AOK Hessen/KV Hessen - Konzeption und Umsetzung einer personenbezogenen Datenbasis aus der Gesetzliche Krankenversicherung.  Gesundheitswesen. 2005;  67 638-645 , (in German)
• 15 Jönsson B. Revealing the cost of type II diabetes in Europe.  Diabetologia. 2002;  45 S5-S12
• 16 Köster I, von Ferber L, Ihle P, Schubert I, Hauner H. The cost burden of diabetes mellitus: the evidence from Germany-the CoDiM Study.  Diabetologia. 2006a;  49 1498-1504
• 17 Köster I, Hauner H, von Ferber L. Heterogeneity of costs of diabetic patients.  Dtsch Med Wochenschr. 2006b;  131 804-810 , (in German)
• 18 Liebl A, Neiß A, Spannheimer A. et al . Kosten des Typ-2-Diabetes in Deutschland. Ergebnisse der CODE-2-Studie.  Dtsch Med Wochensch. 2002a;  126 585-589 , (in German)
• 19 Liebl A, Spannheimer A, Reitberger U, Gortz A. Kosten für Spätkomplikationen bei Diabetes mellitus Typ 2 in Deutschland. Ergebnisse der CODE-2 Studie.  Med Klin. 2002b;  97 713-719 , (in German)
• 20 National Association of Statutory Health Insurance Physicians (KBV) .(Ed.) Uniform Value Scale (EBM), 1 October 2001. Ulm: Deutscher Ärzte-Verlag 2001
• 21 O'Brien JA, Patrick AR, Caro J. Estimates of direct medical costs for microvascular and microvascular complications resulting from Type 2 diabetes mellitus in the United States in 2000.  Clin Ther. 2003;  25 1017-1038
• 22 Rathmann W, Haastert B, Roseman JM, Gries FA, Giani G. Prescription drug use and costs among diabetic patients in primary health care practices in Germany.  Diabetes Care. 1998;  21 389-397
• 23 Ray JA, Valentine WJ, Secnik K, Oglesby AK, Cordony A, Gordeois A. et al . Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain.  Cur Med Res Opin. 2005;  21 1617-1629
• 24 Redekop WK, Koopmanschap MA, Rutten GE, Wolffenbuttel BH, Stool RP, Niessen LW. Resource consumption and costs in Dutch patients with type 2 diabetes mellitus: results from 29 general practices.  Diabet Med. 2002;  19 246-253
• 25 Selby JV, Ray GT, Zhang D, Colby CJ. Excess costs of medical care for patients with diabetes in a managed care population.  Diabetes Care. 1997;  20 1396-1402
• 26 Seufert J. Cardiovascular outcome studies in typ 2 diabetes therapy.  Deutsches Ärzteblatt. 2006;  14 765-770
• 27 Simpson SH, Corabian P, Jacobs P, Johnson JA. The cost of major comorbidity in people with diabetes mellitus.  CMAJ. 2003;  168 1661-1667
• 28 Social Security Code .31st edition München: Deutscher Taschenbuch Verlag 2004
• 29 Stock SAK, Redaelli M, Wendland G, Civello D, Lauterbach W. Diabetes-prevalence and cost of illness in Germany: a study evaluating data from the statutory health insurance in Germany.  Diabet Med. 2005;  23 299-305
• 30 Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA. et al . Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.  BMJ. 2000;  321 405-412
• 31 Williams R, Van Gaal L, Lucioni C. Assessing the impact of complications on the costs of type II diabetes.  Diabetologia. 2002;  45 13-17

1 Conflict of interest
The study was financially supported by the German Diabetes Foundation, Aventis Pharma Germany GmbH, and Pfizer Germany GmbH with unrestricted grants.

Correspondence